Jinyu Bio-technology Co., Ltd.

SHSE:600201 Stock Report

Market Cap: CN¥7.6b

Jinyu Bio-technology Valuation

Is 600201 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600201 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600201 (CN¥6.92) is trading above our estimate of fair value (CN¥1.43)

Significantly Below Fair Value: 600201 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600201?

Key metric: As 600201 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600201. This is calculated by dividing 600201's market cap by their current earnings.
What is 600201's PE Ratio?
PE Ratio46.9x
EarningsCN¥164.86m
Market CapCN¥7.58b

Price to Earnings Ratio vs Peers

How does 600201's PE Ratio compare to its peers?

The above table shows the PE ratio for 600201 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.5x
002038 Beijing SL Pharmaceutical
92.5xn/aCN¥7.5b
300406 Beijing Strong BiotechnologiesInc
16.6x23.2%CN¥8.7b
301047 Sino BiologicalInc
54.9x24.9%CN¥8.3b
300841 Chengdu Kanghua Biological Products
13.9x18.0%CN¥7.5b
600201 Jinyu Bio-technology
46.9x47.1%CN¥7.6b

Price-To-Earnings vs Peers: 600201 is expensive based on its Price-To-Earnings Ratio (46.9x) compared to the peer average (44.5x).

Price to Earnings Ratio vs Industry

How does 600201's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600201 46.9xIndustry Avg. 36.6xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600201 is expensive based on its Price-To-Earnings Ratio (46.9x) compared to the CN Biotechs industry average (36.6x).

Price to Earnings Ratio vs Fair Ratio

What is 600201's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600201 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio46.9x
Fair PE Ratio38.7x

Price-To-Earnings vs Fair Ratio: 600201 is expensive based on its Price-To-Earnings Ratio (46.9x) compared to the estimated Fair Price-To-Earnings Ratio (38.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 600201 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥6.92
CN¥7.94
+14.8%
21.6%CN¥11.00CN¥6.00n/a5
Nov ’25CN¥6.66
CN¥7.94
+19.2%
21.6%CN¥11.00CN¥6.00n/a5
Oct ’25CN¥7.30
CN¥7.94
+8.8%
21.6%CN¥11.00CN¥6.00n/a5
Sep ’25CN¥6.26
CN¥8.34
+33.2%
22.8%CN¥11.00CN¥6.00n/a5
Aug ’25CN¥6.75
CN¥9.14
+35.4%
20.9%CN¥11.00CN¥6.70n/a5
Jul ’25CN¥7.27
CN¥9.52
+30.9%
16.1%CN¥11.00CN¥7.00n/a5
Jun ’25CN¥8.94
CN¥9.38
+4.9%
17.5%CN¥11.00CN¥7.00n/a5
May ’25CN¥9.14
CN¥9.38
+2.6%
17.5%CN¥11.00CN¥7.00n/a5
Apr ’25CN¥8.96
CN¥9.48
+5.7%
22.0%CN¥12.00CN¥7.00n/a4
Mar ’25CN¥8.69
CN¥10.29
+18.5%
14.6%CN¥12.00CN¥8.00n/a5
Feb ’25CN¥7.99
CN¥10.29
+28.8%
14.6%CN¥12.00CN¥8.00n/a5
Jan ’25CN¥10.77
CN¥10.29
-4.4%
14.6%CN¥12.00CN¥8.00n/a5
Dec ’24CN¥10.33
CN¥10.29
-0.3%
14.6%CN¥12.00CN¥8.00n/a5
Nov ’24CN¥9.44
CN¥10.29
+9.0%
14.6%CN¥12.00CN¥8.00CN¥6.665
Oct ’24CN¥9.41
CN¥10.29
+9.4%
14.6%CN¥12.00CN¥8.00CN¥7.305
Sep ’24CN¥9.44
CN¥10.33
+9.5%
13.9%CN¥12.00CN¥8.20CN¥6.265
Aug ’24CN¥10.15
CN¥11.54
+13.7%
20.8%CN¥14.00CN¥8.20CN¥6.755
Jul ’24CN¥9.51
CN¥11.54
+21.3%
20.8%CN¥14.00CN¥8.20CN¥7.275
Jun ’24CN¥10.31
CN¥11.54
+11.9%
20.8%CN¥14.00CN¥8.20CN¥8.945
May ’24CN¥10.76
CN¥11.92
+10.8%
16.2%CN¥14.00CN¥9.50CN¥9.145
Apr ’24CN¥11.88
CN¥12.42
+4.5%
19.2%CN¥15.40CN¥9.50CN¥8.965
Mar ’24CN¥12.48
CN¥12.42
-0.5%
19.2%CN¥15.40CN¥9.50CN¥8.695
Feb ’24CN¥11.31
CN¥11.28
-0.3%
21.4%CN¥15.40CN¥9.50CN¥7.994
Jan ’24CN¥9.01
CN¥11.28
+25.1%
21.4%CN¥15.40CN¥9.50CN¥10.774
Dec ’23CN¥8.94
CN¥11.28
+26.1%
21.4%CN¥15.40CN¥9.50CN¥10.334
Nov ’23CN¥8.63
CN¥10.90
+26.3%
25.2%CN¥15.40CN¥8.00CN¥9.444

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

7D

-3.9%

1Y

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

7D

-2.0%

1Y

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.72

7D

-1.2%

1Y

18.8%